Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

46.28
+0.12000.26%
Volume:37.17K
Turnover:1.71M
Market Cap:1.60B
PE:-11.68
High:46.45
Open:46.02
Low:45.06
Close:46.16
Loading ...

Disc Medicine price target raised to $70 from $62 at Scotiabank

TIPRANKS
·
05 Nov 2024

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
05 Nov 2024

Scotiabank Reaffirms Their Buy Rating on Disc Medicine (IRON)

TIPRANKS
·
05 Nov 2024

Morgan Stanley Upgrades Disc Medicine to Overweight From Equalweight, Price Target is $85

MT Newswires Live
·
05 Nov 2024

Disc Medicine Inc : Leerink Partners Raises Target Price to $85 From $65

THOMSON REUTERS
·
05 Nov 2024

Disc Medicine Inc : Raymond James Raises to Strong Buy From Outperform; Raises Target Price to $110 From $66

THOMSON REUTERS
·
05 Nov 2024

Disc Medicine’s Prospects Brighten with Accelerated Approval Potential for Bitopertin

TIPRANKS
·
05 Nov 2024

Disc Medicine upgraded to Overweight from Equal Weight at Morgan Stanley

TIPRANKS
·
05 Nov 2024

Positive Regulatory Update and Market Potential Boost Disc Medicine’s Bitopertin Prospects

TIPRANKS
·
05 Nov 2024

Disc Medicine price target raised to $112 from $70 at BMO Capital

TIPRANKS
·
05 Nov 2024

Disc Medicine Shares Rise After Positive Feedback From FDA

Dow Jones
·
05 Nov 2024

Disc Medicine to Initiate Apollo Trial After Phase 2 Meeting With FDA for Bitopertin in Erythropoietic Protoporphyria

MT Newswires Live
·
05 Nov 2024

Wedbush Adjusts Disc Medicine Price Target to $75 From $60, Maintains Outperform Rating

MT Newswires Live
·
04 Nov 2024

BUZZ-Disc Medicine surges on positive FDA feedback for genetic disorder drug

Reuters
·
04 Nov 2024

Disc Medicine’s Bitopertin Advances Towards Accelerated FDA Approval: A Positive Outlook

TIPRANKS
·
04 Nov 2024

Analyst Recommends ‘Buy’ for Disc Medicine Due to Promising Developments in Bitopertin’s Accelerated Approval Pathway

TIPRANKS
·
04 Nov 2024

Disc Medicine upgraded at Raymond James as bitopertin ‘uber bull case plays out’

TIPRANKS
·
04 Nov 2024

Disc Medicine Shares up 26.6% on FDA's Positive Feedback Supporting the Development Path for Co's Genetic Disorder Drug

THOMSON REUTERS
·
04 Nov 2024

Disc Medicine upgraded to Strong Buy from Outperform at Raymond James

TIPRANKS
·
04 Nov 2024

Disc Medicine Shares up 26% Premarket on FDA's Positive Feedback Supporting the Development Path for Co's Genetic Disorder Drug

THOMSON REUTERS
·
04 Nov 2024